PTGS2 and peptic ulcer disease: Lin et al. [14] reported that cyclooxygenase-2 selective inhibitors (coxibs) significantly increased the incidence of UGIB, and various risk factors, including age, male gender, history of uncomplicated peptic ulcer disease, peptic ulcer bleeding, and H. pylori infection, contributed to the development of UGIB in coxibs users.